Advantage of 188Re-radiopharmaceuticals in hepatocellular cancer and liver metastases [4]

Journal of Nuclear Medicine

Volumn 46, Issue 8, 2005, Pages 1407-

  Liepe, Knut ^a   Kotzerke, Jorg ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 HEXADECYL 1,2,9,9 TETRAMETHYL 4,7 DIAZA 1,10 DECANETHIOL RE 188; BISPHOSPHONIC ACID DERIVATIVE; HUMAN SERUM ALBUMIN RE 188; IODINATED POPPYSEED OIL; RADIOACTIVE MICROSPHERE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 188RE 4 HEXADECYL 1,2,9,9 TETRAMETHYL 4,7 DIAZA 1,10 DECANETHIOL LIPIODOL CONJUGATE; 188RE-4-HEXADECYL-1,2,9,9-TETRAMETHYL-4,7-DIAZA-1,10-DECANETHIOL LIPIODOL CONJUGATE; ORGANOMETALLIC COMPOUND;

ARTIFICIAL EMBOLISM; COLON CANCER; DRUG HALF LIFE; DRUG STABILITY; DRUG URINE LEVEL; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER SINUSOID; NONHUMAN; PARTICLE SIZE; PERFUSION; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY; VISCOSITY; AGED; ANTIBODY SPECIFICITY; FEMALE; LIVER TUMOR; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NOTE; TISSUE DISTRIBUTION;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IODIZED OIL; LIVER NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 25444447368     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med. 2005;46:60-66.
2. 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J Nucl Med. 2003;44:953-960.
3. Wunderlich G, Pinkert J, Andreeff M, et al. Preparation and biodistnbution of rhenium-188 labeled albumin microspheres B 20: a promising new agent for radiotherapy. Appl Radiat Isot. 2000;52:63-68.
4. 188Re] human serum albumin microspheres for therapeutic use in nuclear medicine. Appl Radiat Isot. 2005;62:915-918.
5. 188Re-lipiodol for locoregional treatment of hepatocellular carcinoma: a phase I study [abstract]. Eur J Nucl Med. 2003;30(suppl 2):S219.
6. 18F-FDG PET. J Nucl Med. 2004;45:1892-1897.
7. Nakajo M, Kobayashi H, Shimabukuro K, et al. Biodistribution and in vivo kinetics of iodine-131 Lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med. 1988;29:1066-1077.
8. Nakamura H, Hashimoto T, Oi H, Sawada S. Iodized oil in the portal vein after arterial embolization. Radiology. 1988;167:415-417.